A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
Trial details
- Registry ID
- NCT05112861
- Drugs studied
- bevacizumab
TrialRedline tracks 5 clinical trials sponsored by Outlook Therapeutics, Inc.: 5 Phase 3.
Company identity checked against sources
Names as written in the registry records.
NCT04516278 · Outlook Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Frequency and Incidence of Treatment-emergent Adverse Events. After: Measure: Number of Participants With Adverse Events.
NCT03834753 · Outlook Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of subjects who gain 15 or more letters in best corrected visual acuity (BCVA). After: Measure: Proportion of Subjects Who Gain 15 or More Letters in Best Corrected Visual Acuity (BCVA).
NCT06190093 · Outlook Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Evaluate the effectiveness of intravitreal injections of ONS-5010 compared to ranibizumab in preventing vision loss, as measured by the mean change in baseline best correct visual acuity (BCVA) at Week 8. After: Measure: Evaluate the Effectiveness of Intravitreal Injections of ONS-5010 Compared to Ranibizumab in Preventing Vision Loss, as Measured by the Mean Change in Baseline Best Correct Visual Acuity (BCVA) at Week 8.
NCT04516278 · Outlook Therapeutics, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Frequency and incidence of treatment-emergent adverse events. After: Measure: Frequency and Incidence of Treatment-emergent Adverse Events.
Before: 195 participants (actual). After: 197 participants (actual).
NCT05112861 · Outlook Therapeutics, Inc.
Before: Mar 2025. After: Dec 2027.